A Gilead Sciences office is shown in Foster City, California, U.S. May 1, 2018.
Stephen Lam | Reuters
Gilead Sciences shares surged by more than 15% in after-hours trading Thursday after an industry publication said Covid-19 patients being treated with the company’s antiviral drug Remdesivir appear to have “rapid recoveries in fever and respiratory symptoms.”
STAT News said a doctor in Chicago overseeing a closely watched clinical trial on the drug found that most of its patients had been discharged in less than a week.
“The best news is that most of our patients have already been discharged, which is